These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6668360)

  • 21. Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Tsujimoto M; Kinoshita F; Okunaga T; Kotani S; Kusumoto S; Yamamoto K; Shiba T
    Microbiol Immunol; 1979; 23(9):933-6. PubMed ID: 576117
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of conjugates between luteinizing hormone releasing hormone (LH-RH) and N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) models of totally synthetic vaccines.
    Bernard JM; Gras-Masse H; Drobecq H; Tartar A; Lefrancier P; Hosmalin A; Carelli C; Chedid L
    Int J Pept Protein Res; 1987 Apr; 29(4):455-63. PubMed ID: 3298096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of conjugates containing N-acetylmuramyl-L-alanyl-D-isoglutaminyl (MDP). Their use as hapten-carrier systems.
    Reichert CM; Carelli C; Jolivet M; Audibert F; Lefrancier P; Chedid L
    Mol Immunol; 1980 Mar; 17(3):357-63. PubMed ID: 7442679
    [No Abstract]   [Full Text] [Related]  

  • 25. An adjuvant formulation based on N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with dimethyldioctadecylammonium chloride and zinc-L-proline complex as synergists.
    Grubhofer N
    Immunol Lett; 1995 Jan; 44(1):19-24. PubMed ID: 7721338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, mass spectral characterization and immunoadjuvant activity of some novel lipophilic derivatives of muramyl dipeptides.
    Jain RK; Gupta CM; Saxena RK; Saxena RP; Saxena KC; Shukla R; Anand N; Costello CE
    Chem Phys Lipids; 1986; 41(3-4):237-64. PubMed ID: 3815623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The adjuvant effect of synthetic glycopeptides on humoral immune response to thymus-dependent antigen].
    Kalina NG; Elkina SI; Moshiashvili IIa; Sergeev VV
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jun; (6):97-100. PubMed ID: 6613423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation of the proliferative response of thymocytes to phytohemagglutinin by the muramyl dipeptide1.
    Iribe H; Koga T
    Cell Immunol; 1984 Oct; 88(1):9-15. PubMed ID: 6332683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro immune response to sheep erythrocytes in macrophage depleted cultures. Restoration with interleukine 1 or a monokine from resident macrophages and stimulation by N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP).
    Souvannavong V; Rimsky L; Adam A
    Biochem Biophys Res Commun; 1983 Jul; 114(2):721-8. PubMed ID: 6603843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
    Staruch MJ; Wood DD
    J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel muramyl peptide derivative stimulates tumoricidal activity of macrophages and antibody production by B cells.
    Tenu JP; Adam A; Souvannavong V; Barratt G; Yapo A; Petit JF; Level M; Clemance M; Douglas K
    FEBS Lett; 1987 Aug; 220(1):93-7. PubMed ID: 3497058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked enhancement of macrophage activation induced by synthetic muramyl dipeptide (MDP) conjugate using monoclonal anti-MDP antibodies.
    Leclerc C; Bahr GM; Chedid L
    Cell Immunol; 1984 Jul; 86(2):269-77. PubMed ID: 6733783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of N-acetyl-muramyl-L-alanyl-D-isoglutamine on interferon production in mice by Newcastle disease virus.
    Sakuma T; Azuma M; Yoshida I
    J Gen Virol; 1984 May; 65 ( Pt 5)():999-1003. PubMed ID: 6202835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
    Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent linkage of the synthetic adjuvant MDP to the synthetic polypeptide (T,G)-A-L changes the specificity of the immune response at the T and B cell level.
    Abehsira-Amar O; Uzan M; Audibert F; Jolivet M; Chedid L; Theze J
    Mol Immunol; 1987 Sep; 24(9):945-51. PubMed ID: 3498888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical modification of the C-6 substituent in the carbohydrate moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP), and the immunoadjuvant activity.
    Okumura H; Tokushima Y; Saiki I; Azuma I; Kiso M; Hasegawa A
    Carbohydr Res; 1983 Oct; 122(1):87-98. PubMed ID: 6652634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of antibodies to muramyl dipeptide in patients with tuberculosis or leprosy.
    Bahr GM; Modabber FZ; Rook GA; Mehrotra ML; Stanford JL; Chedid L
    Clin Exp Immunol; 1982 Jan; 47(1):53-8. PubMed ID: 6807589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody to calmodulin: development, characterization, and comparison with polyclonal anti-calmodulin antibodies.
    Sacks DB; Porter SE; Ladenson JH; McDonald JM
    Anal Biochem; 1991 May; 194(2):369-77. PubMed ID: 1862939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.